Key result
Prasugrel was approved by the FDA for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Why the study?
Does prasugrel reduce thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Population
Patients with acute coronary syndrome who undergo percutaneous coronary intervention
Design
Editorial
Authors
Loading...
The FDA approved prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Does prasugrel reduce thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
The FDA approved prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Ellis F. Unger (2009) conducted a review in Acute coronary syndrome undergoing percutaneous coronary intervention. Prasugrel was evaluated on Thrombotic cardiovascular events. Prasugrel was approved by the FDA for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.